We aimed to develop a novel method to automatically analyze HER2 ITH and determine the clinical association of high HER2 heterogeneity with a poor prognosis due to resistance to postoperative adjuvant therapies with HER2-targeted agents in primary breast cancer, through the application of GMM analysis. This evidence concerns the gene ERBB2 and breast carcinoma.